Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript

Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023

Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry of Live Site Advisors. Thank you. You may begin.

Dan Ferry: Thank you, operator, and good afternoon, everyone. With me today on the phone are Avanish Vellanki, Chief Executive Officer of Rain Oncology; Robert Doebele, Chief Scientific Officer; Richard Bryce, Chief Medical Officer; and Nelson Cabatuan, SVP of Finance. During today's call, Avanish will provide an update on the broader strategic vision for the milademetan franchise. Bob will review the biology and rationale of p53 reactivation as it relates to our milademetan clinical program. Richard will provide an update on Rain's clinical strategy, and Nelson will review the financials. Before we begin, I would like to remind you that statements made during this conference call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements are based upon Rain's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties as described in Rain's annual report on Form 10-K for the year ended December 31, 2021 filed with Securities and Exchange Commission and other SEC filings. All forward-looking statements made during this conference call are based on management's assumptions in estimates as of today, March 9, 2023. Rain undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after today, except as required by law.

With that, I'd like to turn the call over to Avanish Vellanki, CEO of Rain Oncology. Avanish?

Avanish Vellanki : Thank you, Dan, and thanks to everyone for joining us for our fourth quarter in full year 2022 earnings highlights and corporate update. To kick things off, we'd like to remind everyone of our name change to Rain Oncology in late 2022 to marker our anticipated growth as a dedicated and focused precision oncology business, we believe our new corporate name better reflects who we are and who we intend to remain. As Rain continues to drive forward with our late stage clinical program milademetan or mila, our oral small molecule inhibitor of the MDM2 p53 complex, we'd like to approach today's call by providing context around our goal of demonstrating how p53 reactivation through mila's disruption of the complex could potentially be transformative in treating a broad range of cancer patients.

In the spirit of this, we anticipate the readout from our mantra study to potentially serve as the first validation of p53 reactivation in a Phase 3 clinical setting. If the MANTRA topline data are favorable, we believe it will signify that reactivation of p53 matters. This will be an important validation as we begin to think about our initiatives beyond de differentiated liposarcoma or DDLPS. On today's call, we'll also provide highlights from our 2022 progress and achievements. As a bit of biology review, we all know that p53 is the good guy in this story. We want active p53 to do what it's supposed to be doing, which is to protect us from cancer. Today, there are no approved therapies in the treatment of cancer that are aimed at restoring or reactivating this innate anti-cancer agent, cancer broadly speaking, needs to find a way to get rid of p53.

We all know that mutations in p53, those instances when p53 is broken and can't bind DNA to allow p53 to do what it's supposed to do occurs in approximately half of all cancers. In the other half, where p53 itself is not broken, cancer has to find other ways to get rid of it. MDM2 is a critical means of deactivating p53 in instances when there are no p53 mutations present. Therefore, in tumors that rely on MDM2 to red cells of p53 impeding the interaction of MDM2 and p53 could be a route to restoring p53 s innate protective properties, and even if MDM2 is not overexpressed, further reactivation or enhancement of wild type p53 levels like further enhance anti-tumor activity of target therapies to address other oncogenic drivers. There are multitude of potential indications to be considered, especially if the tolerability profile a mila enables a wide-ranging set of combination partners.

We believe a positive outcome in the mantra study would legitimize p53 reactivation as a route to treat a range of p53 wild-type cancers. And in that scenario, milademetan could be the first inhibitor of the MDM2 p53 complex to be submitted and possibly approved by the FDA and other regulatory authorities around the world. Bob will provide additional color on the p53 reactivation story along with insights from the recent publication in the Journal of Clinical Oncology, before Richard discusses how those data support the novel dose regimen of milademetan, which is optimized to reduce toxicities associated with MDM2 p53 inhibition. Our clinical strategy while starting in DDLPS. Based on the totality of the data present at the tunnel of licensing, the program in 2020 will aggressively move to larger patient populations.

Based on the experience we have gained with mila in the clinic, would point out that after our initial indication in DDLPS targeting approximately 1,400 patients per year in the US. Our subsequent studies in the MANTRA-2 basket study targets 8,000 patients per year in the US and our third plan study, the MANTRA-4 study will target over 40,000 patients per year domestically. That pattern should convey how we approach creating value for the mila franchise and as we evaluate the potential of both monotherapy and combination opportunities approximately 50% of the cancer population possessing wild type p53 tumors. I'll ask Bob and Richard to talk in more detail around recent data presented and the clinical strategy for milademetan. I do want to comment briefly, however, on our preclinical research program focused on developing an inhibitor of RAD52, we have made a strategic determination to terminate this program based on data we have generated for the RAD52 research effort.

We do not anticipate a meaningful probability of success. Therefore, we are electing to focus our resources on identifying new indications for milademetan or additional precision oncology programs by external licensing or internal development that may represent a more efficient deployment of capital for Rain. In the prior quarter, we also remind you that we further improved our cash position with a $50 million registered offering concurrent with the release of the early MANTRA-2 data. We're excited to welcome several new large healthcare focused funds to Rain as part of that financing. Our year-end cash position of approximately $130 million provides runway to complete all current, ongoing and planned clinical trials of milademetan. This includes the Phase 3 MANTRA trial in DDLPS for which data is expected in the second quarter of this year.

It includes the ongoing Phase 2 MANTRA-2 basket trial and the planned Phase 1/2 MANTRA-4 basket trial, which we expect to commence by mid-year. With that, I'd like to turn it over to our President and Chief Scientific Officer, Dr. Bob Dobel. Bob.

Robert Doebele : Thanks, Avanish. Let's start by continuing the discussion around the rationale for p53 reactivation is a treatment strategy and cancer. MDM2 is a negative regulator of p53, blocking p53 transcriptional activity promoting p53 export from the nucleus and ultimately targeting the p53 protein for degradation. Best dysregulated MDM2 can provide an alternate and important mechanism for p53 loss in tumor cells and therefore facilitates on immunogenicity. MDM2 upregulation can occur through a number of different mechanisms, including MDM2 gene amplification, MDM2 overexpression, and or MDM2 regulator loss. p14ARF is a negative regulator of MDM2 activity and is encoded by the CDKN2A gene, which is lost in a large percentage of cancers.

In January of this year, we published clinical trial data from the prior Phase 1 study of milademetan in the Journal of Clinical Oncology or JCO. This detailed the results of the first-in-class human Phase 1 study of milademetan that evaluated the safety, PK/PD and preliminary efficacy in patients with advanced liposarcoma, solid tumors or lymphomas. These results indeed showed restoration of p53 levels and activity in patients with various cancers. Tumor biopsies of patients treated with milademetan showed increased p53 protein levels and increased expression of p53 gene targets such as p21. Additional pharmacodynamic marker testing showed an exposure dependent increase in the p53 target gene MIC-1 or GDF-15 in patient blood samples following treatment with milademetan.

Although, all tested DDLPS, patients had MDM2 amplification, median PFS, and DDLPS patients did not differ by levels of key biomarkers, including MDM2 or CDK4 copy number, nor by mRNA expression levels of MDM2, CDK4, or MDM4. These data are consistent with our preclinical data showing that while MDM2 amplification is an important biomarker, higher levels of gene amplification do not correlate with increased milademetan sensitivity or improved clinical outcomes with MDM2 inhibitor treatment. Moving on to the MANTRA-2 basket study, we continue to enroll patients with MDM2 amplified p53 wild type solid tumors and plan to expand to additional sites worldwide with the goal of targeting full enrollment of approximately 65 patients across a range of solid tumors.

Regarding the upcoming MANTRA-4 study, there is significant biological rationale to pursue combination of milademetan and an immune checkpoint inhibitor. In this case, Roche's atezolizumab or Tecentriq. CDKN2A encodes a critical regulator of the MDM2 p53 pathway. p14ARF. Loss of the CDKN2A gene therefore leads to increased MDM2 activity and decreased p53 levels in tumors. Preclinical work confirms that cancer signs with both CDKN2A loss and wild-type p53 are sensitive to milademetan. Furthermore, CDKN2A loss is associated with poor clinical outcomes in patients with non-small cell lung cancer, bladder cancer, and melanoma treated with immune checkpoint inhibitors. Even in those patients with favorable predictive biomarkers such as high PD-L1 or high TMB.

Reactivation of p53 has been shown to lead to enhanced immune surveillance due to increased MHC class one antigen presentation, interferon gamma signaling, and other mechanisms. Based on this rationale, we are excited to launch the MANTRA-4 study in patients with CDKN2A loss, and wild type p53, a population that could include more than 40,000 patients with solid tumors annually in the U.S. The demonstrated ability of milademetan to reactivate p53 both in cancer models and in patients, as well as our early MANTRA-2 trial results have demonstrated that the MDM2 p53 complex matters in cancer biology. We have shown that milademetan and an inhibitor of the MDM2 p53 complex restores wild type p53. Thus, milademetan should not be limited to liposarcoma as it may become part of a broader strategy to reactivate p53 and numerous tumor types that harbor wild-type p53.

Ultimately, up to 50% of cancers may be addressable by disrupting the MDM2 p53 interaction. Given the critical importance of p53 and the large number of patients potentially affected by MDM2 mediated p53 loss, there's a great interest in targeting the MDM2 p53 complex to restore p53 activity. And finally, as Avanish mentioned, we have terminated the RAD52 preclinical research program. Although the RAD52 pathway is likely to be critical in BRCA deficient tumors, we did not achieve meaningful success with our early research efforts around this target because we determined that the current biochemical assays to screen novel RAD52 inhibitors did not correlate with the desired cellular effect of potency and selectivity. While we continue to evaluate additional avenues to innovate with biomarker driven precision therapeutic strategies, we believe a better use of resources from the research team will be to evaluate the additional potential for milademetan across new indications.

In addition to evaluating other novel cancer targets. At this point, I will hand it over to our Chief Medical Officer, Richard Bryce, to discuss additional updates around RAIN'S clinical trial pipeline. Richard?

Easiest Md/PhD Programs to Get Into

Pressmaster/Shutterstock.com

Richard Bryce: Thank you, Bob, and good afternoon everyone. As both Avanish and Bob iterated, we recently published in the JCO the results from the Phase 1 first in human study of milademetan that evaluated the safety, PK, PD and preliminary efficacy in a range of tumor types, including de differentiated liposarcoma. We have adopted a novel intermittent docent schedule of 260 milligrams daily, given for three out of 14 days. Preliminary results from this study demonstrated encouraging single agent activity in DDLPS, prompting our randomized Phase 3 MANTRA trial from which we expect top line data in the second quarter of 2023. Among the 53 DDLPS patients in the Phase 1 trial published in the JCO, the median progression-free survival of all patients, regardless of dose and schedule was 7.2 months, which is already longer than that observed that the current standards of care have trabectedin or eribulin of approximately two months.

And as previously discussed, for those patients who received the optimized dose and schedule of milademetan, the median PPF was 7.4 months. And within this cohort of 16 patients, when we exclude the five treatment naive patients, the median PPF was actually 8.0 months. We believe these data further support the opportunity for milademetan to exhibit a favorable outcome in a pivotal mantra study. Moving on to our phase three mantra study, we previously announced that we had completed enrollment of 175 patients five months ahead of our prior year end 2022 guidance. We believe the accelerated enrollment completion speaks to the tremendous unmet need in patients with DDLPS, for which milademetan offers a targeted therapeutic strategy relative to standard cytotoxic options.

We continue to affirm our expectations for top line data in the second quarter. As a reminder, this is an event driven trial requiring at least 105 progression events to trigger the primary PFS analysis, and our revised guidance to top line data readout reflects the number of PFS events taking longer to occur than originally anticipated. Rain met with the FDA and DMA prior to the start of the MANTRA study regarding the potential filing for marketing authorization, and we anticipate that if the MANTRA data are supportive, we would intend to submit an NDA Milademetan DDLPS in the United States with similar submissions in Europe and possibly other regions as well. Moving on to the MANTRA-2 Basket study of milademetan in patients with MDM2 amplified tumors.

We provided an update on the last quarter's call with the latest data cut-off date of October 26th, 2022, and at that time we reported two unconfirmed partial responses and two near-PRs, using the same three out of 14-day dosing schedule in this study, safety was consistent with what was reported in a prior Phase 1 study, with no new safety signals being observed. The toxicity profile and adverse event frequencies are consistent with the previous experience at this docent schedule, and also is published in the JCO paper earlier referenced. We view these early data as encouraging with respect to both anti-tumor activity and safety, particularly in this histologically and genetically diverse set of patients. Per our initial protocol, we are continuing to enroll up to 65 patients, and we'll be expanding the study to new sites, including several outside the U.S. At present, we have 12 active sites in the United States.

We are not providing guidance on the next data update from the MANTRA-2 study at this time. We previously stated that it would be most logical to present an update from the MANTRA-2 study when the data revealed the path forward. The MANTRA-2 study was designed with melanoma monotherapy across all solid tumors, exhibiting a certain degree of MDM2 amplification, and if the data support meaningful confirmed responses across a range of cancers, we would intend to pursue a discussion with the FDA to better understand the requirements for a tumor agnostic registrational filing. That is the preferred path, let's call it path A. The timing of those discussions with the FDA, if at all, will be driven by the data path. B, on the other hand, might represent a scenario where data suggests preferential activity in one or more tumor types, but not broad sensitivity.

In this scenario, rain might consider implementing tumor specific expansion cohorts in the MANTRA-2 trial as part of a protocol amendment. In the event that milademetan were to not show sustained meaningful monotherapy activity across a broad range of tumors, path C, might involve evaluation of a combination strategy. The most logical time to present an update on the MANTRA-2 trial will therefore be when we are better informed by the data to better understand which of those three potential paths might be the most appropriate way forward. Onto MANTRA-4. This is a Phase 1, 2 trial designed to enroll 30 patients with wild type P53 advanced solid tumors that also exhibit loss of function of the CDKN to AG. This strategy could target over 40,000 patients per year in the US.

We expect the start of MANTRA-4, a second tumor agnostic basket study in the middle of the year. This trial will be our first combination regimen with milademetan, using a checkpoint inhibitor in this case Roche's Tecentriq or atezolizumab. We recently pushed back the start of MANTRA-4 from the first quarter to middle of the year to accommodate the FDA's suggestions around this trial protocol study design. With multiple clinical strategies for milademetan underway and in planning, we are excited by all the emerging and potential new clinical data and the associated potential commercialization opportunities and benefits for patients, while providing a potentially best in class MDM2 inhibitor for patients across multiple tumor types. With that, let me now turn it over to Nelson to review our financial results.

Nelson?

Nelson Cabatuan : Thank you, Richard, and good afternoon everyone. I am pleased to provide an update for financial results for the fourth quarter and full year ended December 31, 2022. I would also like to invite you to review a Form 10-K filed today for more details. For the three months and year end of December 31, 2022, Rain reported a net loss of $22.7 million and $75.7 million respectively as compared to a net loss of $18 million and $51.4 million for the same periods in 2021 respectively. Net loss per share for the three months and year end of December 31, 2022 was $0.70 and $2.71 respectively as compared to a net loss per share of $0.06 to $0.08 and $2.65 for the same periods in 2021 respectively. Research and development expenses for $19.1 million and $61.4 million for the three months and year end of December 31, 2022 respectively, as compared to $14.7 million and $40.8 million for same periods in 2021 respectively.

The increases were primarily related to clinical trials, cost for mila higher payroll related costs for our R&D personnel and various other R&D costs per mila. Non-cash stock-based compensation expenses included in R&D expenses were approximately $1million and $3.8 million in the three months and year end of December 31, 2022 respectively as compared to $1.1 million and $2.5 million in the same period in 2021 respectively. General and administrator expenses were $4.5 million and $15.7 million for the three months and year end of December 31, 2022 respectively as compared to $3.4 million and $10.7 million for the same periods in 2021 respectively. The increases were primarily due to the higher period related cost for Rain's G&A personnel, outside consulting, legal cost, and various third-party G&A costs.

Non-cash stock-based compensation expense included in G&A expenses were approximately $0.3 million and $1.1 million for the three months and year ended December 31, 2022 respectively as compared to $0.2 million and $0.6 million were the same periods in 2021 respectively. Total non-cash stock-based compensation expenses for approximately $1.3 million and $4.9 million for the three months and year end of December 31, 2022 respectively, as compared to $1.3 million and $3.1 million for the same periods in 2021 respectively. As of December 31, 2022, Rain had $130.5 million in cash, cash equivalents and short term investments. Rain will not provide guidance in cash runway at this time. We will continue to assess our cash runway and provide further guidance if appropriate after the release of our MANTRA top line results in the second quarter of this year.

As of December 31, 2022, Rain had approximately 36.3 million shares of common stock outstanding. With that, I'll turn to call back over at Avanish.

Avanish Vellanki: Thanks, Nelson. With that, we'll be happy to answer any questions. Operator?

See also 15 Stocks That Have Increased Dividends for 25 Years and 12 Biggest Cloud Providers by Market Share.

To continue reading the Q&A session, please click here.